参考文献/References:
[1] 董蕾,田颖,刘肆仁,等.沙库巴曲缬沙坦钠片对慢性心力衰竭患者的疗效及对神经内分泌激素活性的影响[J].中国医药,2019,14(5):23-26.
DONG L,TIAN Y,LIU S R,et al.Efficacy of sacubitril/valsartan sodium tablets in treatment of chronic heart failure and the effect on neuroendocrine hormone activity[J].Chin Med,2019,14(5):23-26.
[2] CHAPLIN S.Sacubitril/valsartan for chronic heart failure:its future potential [J].Aust Prescr,2016,27(11):26-34.
[3] CHEN C,WU X,LI Y F,et al.Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI) [J].Ann Palliat Med,2021,10(5):5455-5461.
[4] 范剑峰,方译,郑春华.沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J].中国临床药理学与治疗学,2019,24(7):810-814.
FAN J F,FANG Y,ZHENG C H.Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J].Chin J Clin Pharm Therap,2019,24 (7):810-814.
[5] TSCHPE C,MESSROGHLI D,SCHNRATH F,et al.Treatment of chronic heart failure:what′s not (yet) in the guidelines[J].Dtsch Med Wochenschr,2015,140(8):556.
[6] PACKER M.Kicking the tyres of a heart failure trial:physician response to the approval of sacubitril/valsartan in the USA [J].Eur J Heart Fail,2016,18(10):1211-1219.
[7] 李静,张亮,郝六一,等.重组人脑利钠肽治疗冠心病失代偿性心力衰竭的安全性及疗效分析[J].中国药物与临床,2018,18(12):2194-2195.
LI J,ZHANG L,HAO L Y,et al.Safety and efficacy of recombinant human brain natriuretic peptide in the treatment of decompensated heart failure of coronary heart disease [J].Chin Remed Clin,2018,18 (12):2194-2195.
[8] WANG Y B,GU X S,FAN W Z,et al.Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction[J].Am J Transl Res,2016,8(1):239-245.
[9] 葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:166-174.
GE J B,XU Y J.Internal medicine [M].8th ed.Beijing:People′s Health Publishing House,2013:166-174
[10] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
CHINESE SOCIETY OF CARDIOLOGY OF CHINESE MEDICAL ASSOCIATION,EDITORIAL BOARD OF CHINESE JOURNAL OF CARDIOLOGY.Guidelines for the diagnosis and management of chronic heart failure[J].Chin J Cardiol,2007,35 (12):1076-1095.
[11] 朱燕波,杜金行,林琳,等.明尼苏达心功能不全生命质量量表中文版的研制及临床试用[J].中华行为医学与脑科学杂志,2010,19(2):178-181.
ZHU Y B,DU J X,LIN L,et al.The translating,editing and testing of the Minnesota living With heart failure questionnaire of Chinese version [J].Chin J Behav Med & Brain Sci,2010,19 (2):178-181.
[12] FALA L.Entresto (sacubitril/valsartan):first-in-class angiotensin receptor neprilysin inhibitor FDA approved for heart failure[J].Am Health Drug Benefits,2016,9(1):78-82.
[13] VECCHIS R D,ARIANO C,BIASE G D,et al.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction:a retrospective cohort study[J].Herz,2019,44(5):425-432.
[14] 陈文文,刘燕琳,李振山,等.沙库巴曲缬沙坦在心衰治疗中的应用:从临床试验到真实世界[J].中国医院药学杂志,2018,38(21):2286-2290.
CHEN W W,LIU Y L,LI Z S,et al.Application of sacubitril/valsartan in the treatment of heart failure:from clinical trial to the real world [J].Chin J Hosp Pharm,2018,38 (21):2286-2290.
[15] KAPLINSKY E.Changing the treatment of heart failure with reduced ejection fraction:clinical use of sacubitril-valsartan combination[J].J Geriatr Cardiol,2016,13(11):914-923.
[16] JHUND P S,MCMURRAY J J V.The neprilysin pathway in heart failure:a review and guide on the use of sacubitril/valsartan[J].Heart,2016,102(17):1342-1347.
[17] PSOTKA M A,SCHILLER N B,WHOOLEY M A,et al.Association of change in 5-year N-terminal fragment of the prohormone brain-type natriuretic peptide with left ventricular structure and function in stable coronary disease[J].J Cardiovasc Med (Hagerstown),2018,19(2):67-72.
[18] 官功昌,刘博,崔倩卫,等.冠心病并发心力衰竭患者中血清CARP和Apelin的变化及其临床意义[J].陕西医学杂志,2013,42(9):1236-1238.
GUAN G C,LIU B,CUI Q W,et al.Changes and clinical significance of serum carp and Apelin in patients with coronary heart disease complicated with heart failure [J].Shaanxi med J,2013,42(9):1236-1238.
[19] 王素青,林英会.冠心病合并慢性心力衰竭患者血清HCY、CF-6、UMA水平及意义[J].解放军预防医学杂志,2017,35(2):142-143,146.
WANG S Q,LIN Y H.Clinical significance of levels of semm HCY,CF-6 and UMA in patients with coronary heart disease complicated by chronic heart failure [J].J Prev Med Chin PLA,2017,35 (2):142-143,146.
相似文献/References:
[1]刘建庄,李金兰,娄清云,等.风湿性心脏病心力衰竭血液流变学改变[J].新乡医学院学报,1992,9(02):108.
[2]苗萍,张喜芳 王延枝.硝酸甘油治疗婴幼儿肺炎心衰疗效观察[J].新乡医学院学报,2000,17(02):129.
[3]任明芬,张三强,张冬红,等.冠心病患者QT间期离散度改变的I临床意义[J].新乡医学院学报,2000,17(03):177.
[4]刘 慧,胡永寸,陈 俭,等.卡维地洛对冠心病心力衰竭患者心室重构和心功能的影响[J].新乡医学院学报,2003,20(01):013.
[5]刘 慧,胡永寸,陈俭。杨庆福.卡维地洛对冠心病心力衰竭患者心室重构和心功能的影响[J].新乡医学院学报,2003,20(01):013.
[6]吕风华,张素荣,张跃光,等.冠状动脉粥样硬化性心脏病合并充血性心力衰竭患者血浆脑钠肽水平的检测[J].新乡医学院学报,2007,24(06):581.
[7]廖燕.老年冠状动脉粥样硬化性心脏病患者心功能与肺动脉压和心电指标的关系[J].新乡医学院学报,2012,29(09):696.
[8]郭鹏,李继红.不同类型冠状动脉粥样硬化性心脏病患者血浆D-二聚体和纤维蛋白原水平变化[J].新乡医学院学报,2012,29(09):698.
[9]李永锋,许志强,韩 鹏,等.冠状动脉粥样硬化性心脏病合并阻塞性睡眠呼吸暂停低通气综合征的临床分析 [J].新乡医学院学报,2012,29(10):784.
[10]舒 毅,陈幼萍,曾春平,等. 2型糖尿病合并冠状动脉粥样硬化性心脏病患者下肢血管病变相关因素分析[J].新乡医学院学报,2015,32(08):785.
[11]高致炳,韩 冬,张 超.冠状动脉粥样硬化性心脏病并发心力衰竭患者血浆脑利钠肽和高敏C反应蛋白水平变化及临床意义[J].新乡医学院学报,2021,38(9):864.[doi:10.7683/xxyxyxb.2021.09.013]
GAO Zhibing,HAN Dong,ZHANG Chao.Clinical significance of the changes of plasma brain natriuretic peptide and high-sensitivity C-reactive protein levels in patients with coronary atherosclerotic heart disease complicated with heart failure[J].Journal of Xinxiang Medical University,2021,38(3):864.[doi:10.7683/xxyxyxb.2021.09.013]